Paper Details

  1. Home
  2. Paper Details

Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.

Author: , BacharachJason, BraswellPuiwah, HeahTheresa, KhouriAlbert S, KopczynskiCasey C, LewisRichard A, SerleJanet B, UsnerDale W

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This double-masked, randomized, noninferiority study compared the IOP-lowering efficacy and safety of netarsudil once daily and timolol twice daily in patients with open-angle glaucoma or ocular hypertension. Netarsudil was noninferior to timolol in reducing IOP, with mean reductions from baseline ranging from 3.9 to 4.7 mmHg for netarsudil and 3.8 to 5.2 mmHg for timolol. No treatment-related serious adverse events were reported for either drug, but timolol was associated with statistically significant reductions in mean heart rate.
Paper Details　
Original Abstract of the Article :
PURPOSE: To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once daily (QD) and timolol twice daily (BID). DESIGN: Double-masked, randomized, phase 3, noninferiority study. METHODS: Patients with open-angle glaucoma or ocular hypertension (unmedicated baseline IOP...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ajo.2019.03.002

データ提供：米国国立医学図書館（NLM）

Netarsudil vs Timolol: A Battle for Lower Intraocular Pressure

The world of [Glaucoma] is a complex one, often involving changes in intraocular pressure (IOP). This study compares the efficacy and safety of two IOP-lowering medications, netarsudil and timolol, using a [randomized controlled trial] design. The researchers found that netarsudil, administered once daily, was noninferior to timolol, administered twice daily, in lowering IOP and was associated with a tolerable safety profile.

A New Oasis in the Desert of Glaucoma

The researchers found that netarsudil effectively lowered IOP in patients with open-angle glaucoma or ocular hypertension, demonstrating noninferiority to timolol. This is significant because netarsudil only needs to be administered once daily, potentially improving patient adherence to treatment. The study also found that netarsudil was associated with a tolerable safety profile, with the most frequent side effect being conjunctival hyperemia.

A Breath of Fresh Air

This study offers a breath of fresh air for patients with glaucoma. It provides a new IOP-lowering medication that is effective, well-tolerated, and convenient to use. The findings suggest that netarsudil could be a valuable addition to the armamentarium of glaucoma treatments.

Dr.Camel's Conclusion

This study reveals the potential of netarsudil as a promising new IOP-lowering medication for glaucoma. Its efficacy, safety, and convenience make it a valuable alternative to existing treatments, offering a potential oasis in the desert of glaucoma management.

Date :
  1. Date Completed 2020-03-05
  2. Date Revised 2020-03-05
Further Info :

Pubmed ID

30862500

DOI: Digital Object Identifier

10.1016/j.ajo.2019.03.002

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.